In vivo metabolite identification of bakuchiol in rats by UPLC/ESI–PDA–QTOF–MS

Multi-technology integrated network pharmacology-based study on phytochemicals, active metabolites, and molecular mechanism of Psoraleae Fructus to promote melanogenesis

ETHNOPHARMACOLOGICAL RELEVANCE

According to the Compendium of Materia Medica (Shizhen Li, Ming dynasty) and Welfare Pharmacy (Song dynasty), Psoraleae Fructus (PF), a traditional Chinese medicine (TCM) has a bitter taste and warm nature, which has the effect of treating spleen and kidney deficiency and skin disease. Although PF has been widely used since ancient times and has shown satisfactory efficacy in treating vitiligo, the active substances and the mechanism of PF in promoting melanogenesis remain unclear.

AIM OF THE STUDY

To explore the active substances and action mechanisms of PF in promoting melanogenesis.

MATERIALS AND METHODS

Firstly, UPLC-UV-Q-TOF/MS was used to characterize the components in PF extract and identify the absorption components and metabolites of PF after oral administration at usual doses in rats. Secondly, the active substances and related targets and pathways were predicted by network pharmacology and molecular docking. Finally, pharmacodynamic and molecular biology experiments were used to verify the prediction results.

RESULTS

The experimental results showed that 15 compounds were identified in PF extract, and 44 compounds, consisting of 8 prototype components and 36 metabolites (including isomers) were identified in rats' plasma. Promising action targets (MAPK1, MAPK8, MAPK14) and signaling pathways (MAPK signaling pathway) were screened and refined to elucidate the mechanism of PF against vitiligo based on network pharmacology. Bergaptol and xanthotol (the main metabolites of PF), psoralen (prototype drug), and PF extract significantly increased melanin production in zebrafish embryos. Furthermore, bergaptol could promote the pigmentation of zebrafish embryos more than psoralen and PF extract. Bergaptol significantly increased the protein expression levels of p-P38 and decreased ERK phosphorylation in B16F10 cells, which was also supported by the corresponding inhibitor/activator combination study. Moreover, bergaptol increased the mRNA expression levels of the downstream microphthalmia-associated transcription factor (MITF) and tyrosinase in B16F10 cells. Our data elucidate that bergaptol may promote melanogenesis by regulating the p-P38 and p-ERK signaling pathway.

CONCLUSIONS

This study will lay a foundation for discovering potential new drugs for treating vitiligo and provide feasible ideas for exploring the mechanism of traditional Chinese medicine.

Plasma pharmacokinetics and cerebral nuclei distribution of major constituents of Psoraleae fructus in rats after oral administration

BACKGROUND

The fruit of Psoralea corylifolia L., Psoraleae fructus (PF), is widely used in traditional Chinese medicine as a well-known herbal tonic. Previous studies have shown that PF and its major constituents may have potential values in the treatment of Parkinson and Alzheimer diseases, though their pharmacokinetics and brain distribution were largely unknown.

PURPOSE

To develop a liquid chromatographic-tandem mass spectrometry (LC-MS/MS) method for simultaneous studies of the plasma pharmacokinetics and cerebral nuclei (including cerebellum, thalamus, brainstem, hippocampus, corpus striatum and cortex) distribution in rats of eleven known PF compounds following as psoralen, isopsoralen, psoralidin, bavachin, bavachinin, isobavachin, isobavachalcone, bavachalcone, neobavaisoflavone, corylifol A, and corylin.

METHODS

Rats were orally administered via gavage at a single dose of PF extract at 1.2 g/kg. The eleven known PF compounds were extracted from rat plasma and cerebral nuclei at different time points, and then determined by the established LC-MS/MS method. Non-compartmental pharmacokinetic profiles were calculated, and the distribution in rat plasma and cerebral nuclei were compared.

RESULTS

The results showed that all the tested compounds were quickly absorbed into rat plasma and distributed almost evenly to the cerebral nuclei. The distribution concentrations at different nuclei varied at one determined time point, but the overall trends were basically similar to the plasma concentration-time results. Psoralen and isopsoralen, the two highest coumarins contained in PF, displayed far higher plasma concentrations (AUC_{0→∞, plasma}≈53,884∼65,578 ng·h/ml) and central nervous system penetration (AUC_{0→∞, brain nuclei} ≈44,659∼65,823 ng·h/g) than the prenylflavonoids (other compounds except psoralidin, AUC_{0→∞, plasma}≈69∼324 ng·h/ml; AUC_{0→∞, brain nuclei} ≈119∼3662 ng·h/g). However, the total brain-to-plasma ratios of the prenylflavonoids were higher than the coumarins, suggesting the prenylflavonoids can more readily enter the brain than the coumarins.

CONCLUSION

The established LC-MS/MS method is sensitive and specific for the simultaneous quantitation of the eleven PF compounds in rat plasma and cerebral nuclei. The results of plasma pharmacokinetics and cerebral nuclei distribution may reveal the possible substance basis for the CNS activities of PF, and highlight the application possibility of PF and its major constituents in the treatment of Parkinson and Alzheimer diseases.

Identification of rotundic acid metabolites after oral administration to rats and comparison with the biotransformation by Syncephalastrum racemosum AS 3.264

The objective of this study was to identify the metabolites of rotundic acid after oral administration to rats and compare the similarities with its biotransformation by Syncephalastrum racemosum AS 3.264 using ultra-high performance liquid chromatography coupled with quadrupole time of flight mass spectrometry. A total of fourteen metabolites were determined based on the mass spectrometry and chromatographic behaviors, among which eleven (M1-M3, M7-M14) and six (M2, M4-M8) metabolites were identified in rats and S. racemosum, respectively. Three identical metabolites (M2, M7 and M8) were found in rats and S. racemosum, indicating that there were metabolic similarities. Moreover, to confirm the results of mass spectrometry, three (M2, M4 and M7) metabolites were obtained by the means of amplifying incubation and their structures were determined by various spectroscopic analyses, and M4 was proved to be a previously undescribed compound. This results showed that in vitro assisted preparation by microbial transformation is a feasible and effective method of obtaining metabolites which are in low amounts and difficult to be prepared in vivo.

Metabolic detoxification of bakuchiol is mediated by oxidation of CYP 450s in liver microsomes

Bakuchiol, one of bioactive compounds isolated from the dried ripe fruits of Psoralea corylifolia L., possesses a variety of pharmacological activities. In this study, the metabolites of bakuchiol in rat liver microsomes as well as their cytotoxicities were studied. A total of eight metabolites were isolated and identified as 14-carboxylbakuchiol (M1), 14,15-dihydroxybakuchiol (M2), 12,13-dihydroxybakuchiol (M3), 15-hydroxybakuchiol (M4), 14-hydroxybakuchiol (M5), bakuchiol hydrate (M6), 15-hydroxybakuchiol acetate (M7), and 14-hydroxybakuchiol acetate (M8). All the metabolites are new compounds except for M3. The main type of biotransformation is oxidation reaction, including hydroxylation, epoxidation and carboxylation. Cytotoxicities of bakuchiol and its metabolites against human kidney-2 (HK-2) cell line were evaluated. The median inhibition concentration (IC₅₀) values of bakuchiol, M4, M6 and M8 were (29.48 ± 0.22) μM, (67.51 ± 6.80) μM, (90.23 ± 3.89) μM, and (86.62 ± 6.08) μM, respectively, and the IC₅₀ values of M1, M2, M3, M5, and M7 were all in excess of 100 μM. To further verify the metabolic reliability, the metabolits of bakuchiol in vivo and the metabolic species variations in human and rat liver microsomes were studied using UPLC-MS/MS method. This study provides valuable information for further investigation of metabolism and toxicity of bakuchiol in vivo.

Characterization of isochlorogenic acid A metabolites in rats using high-performance liquid chromatography/quadrupole time-of-flight mass spectrometry

Isochlorogenic acid A is widely present in fruits, vegetables and herbal medicines, and is characterized by anti-inflammatory, hepatoprotective and antiviral properties. However, little is known about its metabolic fate and pharmacokinetic properties. This study is thus designed to investigate the metabolic fate of isochlorogenic acid A. An analytical method based on high-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (HPLC/Q-TOF MS) was established to characterize the metabolites of isochlorogenic acid A in the plasma, urine and feces of rats. A total of 32 metabolites were identified. The metabolic pathways mainly include hydrolyzation, dehydroxylation, hydrogenation and conjugation with methyl, glucuronic acid, glycine, sulfate, glutathione and cysteine. Moreover, the pharmacokinetic profiles of all the circulating metabolites were investigated. M11 resulting from hydrolyzation, dehydroxylation and hydrogenation was the dominant circulating metabolite after the intragastric administration of isochlorogenic acid A. The results obtained will be useful for further study of elucidating potential bioactive metabolites which can provide better explanation of the pharmacological and/or toxicological effects of this compound.

Characterization of human UDP-glucuronosyltransferases responsible for glucuronidation and inhibition of norbakuchinic acid, a primary metabolite of hepatotoxicity and nephrotoxicity component bakuchiol inPsoralea corylifolia L

Norbakuchinic acid (NBKA) is the most abundant metabolite of bakuchiol (a hepatotoxicity and nephrotoxicity component inPsoralea corylifoliaL.) in plasma and urine.

Identification of UDP-glucuronosyltransferases 1A1, 1A3 and 2B15 as the main contributors to glucuronidation of bakuchiol, a natural biologically active compound

1. Bakuchiol, one of the main active compounds of Psoralea corylifolia, possesses a variety of pharmacological activities such as anti-tumor and anti-aging effects. Here, we aimed to characterize the glucuronidation of bakuchiol using human liver microsomes (HLM) and expressed UDP-glucuronosyltransferase (UGT) enzymes. 2. The glucuronide of bakuchiol was confirmed by liquid chromatography-mass spectrometry (LC-MS) and β-glucuronidase hydrolysis assay. Glucuronidation rates and kinetic parameters were derived by enzymatic incubation and model fitting. Activity correlation analyses were performed to identify the main UGT isoforms contributing to hepatic metabolism of bakuchiol. 3. Among the three UGT enzymes (i.e., UGT1A1, UGT1A3 and UGT2B15) capable of catalyzing bakuchiol glucuronidation, UGT2B15 showed the highest activity with a CL_int value of 100 μl/min/nmol. Bakuchiol glucuronidation was strongly correlated with glucuronidation of 5-hydroxyrofecoxib (r = 0.933; p < 0.001), 3-O-glucuronidation of β-estradiol (r = 0.719; p < 0.01) and significantly correlated with 24-O-glucuronidation of CDCA (r = 0.594; p < 0.05). In addition, a marked species difference existed in hepatic glucuronidation of bakuchiol. 4. In conclusion, UGT1A1, UGT1A3 and UGT2B15 were identified as the main contributors to glucuronidation of bakuchiol.

Characterization of glutathione conjugates derived from reactive metabolites of bakuchiol

Bakuchiol belongs to a family of monoterpene phenols occurring in plant Psoralea corylifolia L., a traditional herbal medicine. Bakuchiol has also demonstrated multiple pharmacologic activities. However, metabolism of bakuchiol had never been investigated. The major objective of the present study was to study the metabolic pathways of bakuchiol in order to identify potential reactive metabolites. A total of five glutathione (GSH) conjugates (M1-M5) were detected in rat/human liver microsomes containing NADPH, GSH, and bakuchiol. M1 and M2 resulted from GSH conjugated on the phenol ring. M3, M4, and M5 were derived from GSH adducted on the side chain. The results displayed that bakuchiol can be bioactivated by oxidation of the phenol moiety to the corresponding ortho-quinone and by epoxidation of the aliphatic side chain to epoxide metabolites. No bakuchiol-derived GSH conjugates were detected in urine of rats given bakuchiol, but six corresponding cysteinylglycine (Cys-Gly) conjugates and mercapturic acids were observed instead. A 2'-iodoxybenzoic acid-mediated oxidation reaction of bakuchiol in the presence of GSH produced M1 and M2, and m-chloroperoxybenzoicacid-mediated oxidation of bakuchiol trapped with GSH generated M3 and M4. The four synthetic metabolites were detected in microsomal incubations. In addition, recombinant P450 enzyme incubations showed that CYP 1A2 was the predominant P450 responsible for the metabolism of bakuchiol. In summary, our results demonstrated that bakuchiol can be bioactivated to quinone and epoxide metabolites. These findings facilitate the understanding of the mechanisms of bakuchiol-induced cytotoxicity.